ALS (Amyotrophic lateral sclerosis, Lou Gehrig’s disease) is very severe but rare, with a prevalence of approximately 4 cases per 100,000 individuals. ALS is approximately twice as common among Veterans, especially those with a history of deployment in certain regions, and unfortunately an effective therapy is still needed. VBRI investigators continue to uncover key factors that are involved in this neuromuscular disorder by studying ALS samples and model systems. The results are pointing to molecular regulators that can be modulated to achieve neuroprotection and are helping to advance the field towards the goal of arresting or reversing neurodegenerative disorders.
